

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Doxatib 500 mg/g powder for use in drinking water for pigs and chickens

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each g of powder contains:

Active substance:

Doxycycline 433 mg
(equivalent to 500 mg of doxycycline hyclate)

Excipient:

Qualitative composition of excipients and other constituents

Tartaric acid

Pale yellow to yellow powder for use in drinking water.

3. CLINICAL INFORMATION

3.1 Target species

Pigs and chickens (broilers, pullets, for reproduction).

3.2 Indications for use for each target species

Pigs: For the treatment of the clinical signs associated with porcine respiratory disease caused by *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, and *Mycoplasma hyopneumoniae* susceptible to doxycycline.

Chickens: Where clinical disease is present in the flock, to reduce mortality, morbidity, and clinical signs and to reduce lesions due to Pasteurellosis caused by *Pasteurella multocida* or to reduce morbidity and lesions in respiratory infections caused by *Ornithobacterium rhinotracheale* (ORT).

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals with an impaired liver function.

Do not use in animals with renal disorders.

Do not use when tetracycline resistance has been detected in the herd/flock due to the potential for cross resistance.

3.4 Special warnings

The uptake of medication by animals can be altered as a consequence of illness. In case of insufficient uptake of drinking water, animals should be treated parenterally.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to doxycycline and may decrease the effectiveness of treatment with other tetracyclines due to the potential for cross-resistance.

Resistance to tetracyclines has also been reported in pig respiratory pathogens (*A. pleuropneumoniae*) in some EU countries.

Due to likely variability (time, geographical) in the occurrence of resistance of bacteria against doxycycline bacteriological sampling and susceptibility testing are recommended. In particular susceptibility of *A. pleuropneumoniae* and *O. rhinotracheale* may differ from country to country and even farm to farm. Use of the veterinary medicinal product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

As eradication of the target pathogens may not be achieved, medication should therefore be combined with good management practices, e.g. good hygiene, proper ventilation, no overstocking.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product may cause contact dermatitis and/or hypersensitivity reactions if contact is made with the skin or eyes (powder and solution), or if the powder is inhaled. People with known hypersensitivity to tetracyclines should avoid contact with the veterinary medicinal product.

Take measures to avoid producing dust when incorporating the veterinary medicinal product into water. Avoid direct contact with skin and eyes when handling the veterinary medicinal product to prevent sensitisation and contact dermatitis.

Inhalation of dust particles should be avoided. Wear impermeable gloves (e.g. rubber or latex) and an appropriate dust mask (e.g. disposable half-mask respirator conforming to European Standard EN149 or a non-disposable respirator to European Standard EN140 with a filter to EN143) when mixing and applying the veterinary medicinal product.

In the event of eye or skin contact, rinse the affected area with large amounts of clean water and if irritation occurs, seek medical attention.

If you develop symptoms following exposure such as skin rash, you should seek medical advice and show this warning to the physician. Swelling of the face, lips or eyes, or difficulty with breathing are more serious symptoms and require urgent medical attention.

Wash hands after handling the veterinary medicinal product.
Do not smoke, eat or drink while handling the veterinary medicinal product.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Pig and chicken:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Allergic condition* Photosensitivity*
--	--

*If suspected adverse reactions occur, treatment should be discontinued.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section "Contact details" of the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Doxycycline has a low affinity for forming complexes with calcium and studies have demonstrated that doxycycline scarcely affects skeleton formation.
In the absence of specific studies the use of the veterinary medicinal product is not recommended during pregnancy or lactation.

3.8 Interaction with other medicinal products and other forms of interaction

Do not combine with antibiotics that are bactericidal e.g. penicillins or cephalosporins.

Absorption of doxycycline can be decreased in the presence of high quantities of calcium, iron, magnesium or aluminium in the diet. Do not administer concurrently with antacids, kaolin and iron preparations.

It is advised that the interval between the administration of the veterinary medicinal product and administration of other products containing polyvalent cations should be 1-2 hours because the latter limit the absorption of tetracyclines.

Doxycycline increases the action of anticoagulants.

3.9 Administration routes and dosage

In drinking water use.

Pigs: the recommended dose is:

12.5 mg doxycycline hyclate (25 mg veterinary medicinal product) per kg body weight per day for 4 consecutive days.

If no improvement in clinical signs is seen within this time, the diagnosis should be reviewed and treatment changed. In case of severe infections the medication period may be prolonged for a maximum of 8 consecutive days as determined by the attending veterinary surgeon.

Chickens: the recommended dose is:

10 mg doxycycline hyclate (20 mg veterinary medicinal product) per kg body weight per day for 3-4 consecutive days in case of infections caused by *P. multocida* and 20 mg doxycycline hyclate (40 mg veterinary medicinal product) per kg body weight per day for 3-4 consecutive days in case of infections caused by *O. rhinotracheale*.

Based on the recommended dose and the number and weight of animals to be treated, the exact daily concentration of the veterinary medicinal product should be calculated according to the following formula:

$$\frac{\text{mg veterinary medicinal product / kg body weight / day}}{\text{average daily water intake (l/animal)}} \times \text{average body weight (kg) of animals to be treated} = \text{mg veterinary medicinal product per litre of drinking water}$$

To ensure a correct dosage, body weight should be determined as accurately as possible.

The intake of medicated water depends on the clinical condition of the animals. In order to obtain the correct dosage, the concentration of doxycycline may need to be adjusted accordingly.

The use of suitably calibrated weighing equipment is recommended if part packs are used. The daily amount is to be added to the drinking water such that all medication will be consumed in 24 hours. Medicated water should be replaced every 24 hours.

It is recommended to prepare a concentrated pre-solution - approximately 100 grams product per litre drinking water - and to dilute this further to therapeutic concentrations if required. Alternatively, the concentrated solution can be used in a proportional water medicator.

Solubility of the veterinary medicinal product is pH dependent and it may precipitate if it is mixed in hard alkaline drinking water. Use at minimum concentrations of 200 mg powder per litre drinking water in areas with hard alkaline drinking water (hardness above 10.2 °d and pH more than 8.1).

Do not store the medicated water in metallic containers.

It should be ensured that all animals intended for treatment should have free access to the drinking facilities.

During the treatment period animals should not have access to other water sources than the medicated water.

Water uptake should be monitored at frequent intervals during medication.

After the end of the medication period, the water supply system should be cleaned appropriately to avoid intake of sub-therapeutic amounts of the active substance.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overdoses up to 1.6 times the recommended dose resulted in no clinical signs that could be attributed to treatment. Poultry tolerate double overdoses of doxycycline (40 mg/kg body weight) without any clinical effect.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Pigs:

- Meat and offal: 4 days

Chickens:

- Meat and offal: 3 days (following a dose rate of 10 mg/kg body weight for 4 days).

- Meat and offal: 9 days (following a dose rate of 20 mg/kg body weight for 4 days).

Do not use within 4 weeks before the start of the laying period.

Not for use in birds producing eggs for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QJ01AA02

4.2 Pharmacodynamics

Doxycycline belongs to the group of the tetracycline antibiotics. These antibiotics share the same basic structure of polycyclic naphthacenecarboxamide.

Doxycycline is primarily a bacteriostatic drug. It exerts its action by inhibiting the protein synthesis of the bacterial cell. Inhibition of bacterial protein synthesis results in disturbance of all functions necessary for the life of bacteria. In particular, cell-division and the formation of the cell wall are impaired.

Doxycycline is a broad-spectrum antibiotic, active against a large number of Gram-positive and Gram-negative, aerobic and anaerobic micro-organisms and Mycoplasmas.

For *Ornithobacterium rhinotracheale* results demonstrate a great variation from high to low susceptibility, depending on the geographical region where isolates came from.

In pig pathogens resistance against doxycycline may also vary; in particular susceptibility figures of *A. pleuropneumoniae* may differ from country to country and even farm to farm.

Four resistance mechanisms acquired by microorganisms against tetracyclines in general have been reported: decreased accumulation of tetracyclines (decreased

permeability of the bacterial cell wall and active efflux), protein protection of the bacterial ribosome, enzymatic inactivation of the antibiotic and rRNA mutations (preventing the tetracycline binding to ribosome). Tetracycline resistance is usually acquired by means of plasmids or other mobile elements (e.g. conjugative transposons). Cross resistance between tetracyclines is common but depends on the mechanism conferring resistance. Due to the greater liposolubility and greater ability to pass through cell membranes (in comparison to tetracycline), doxycycline retains a certain degree of efficacy against microorganisms with acquired resistance to tetracyclines via efflux pumps. However, resistance mediated by ribosomal protection proteins confer cross-resistance to doxycycline.

4.3 Pharmacokinetics

Doxycycline is absorbed in the stomach and the first part of the duodenum. Compared to the older tetracyclines the absorption of doxycycline is less affected by the presence of bivalent cations in food. Bioavailability in non-fasted pigs is approximately 21%.

Following oral administration at a dose of 12.8 mg/kg body weight, steady state concentrations during medication range between a C_{min} of 0.40 µg/ml in the early morning to a C_{max} of 0.87 µg/ml in the late afternoon in pigs.

Following administration of doxycycline hyclate at an actual dose of 21 mg/kg body weight to chickens mean plasma concentrations above 1 µg/ml were reached within 6 hours and lasted for 6 hours after cessation of medication. From 24 h up to 96 h after start of treatment the doxycycline plasma concentrations exceeded 2 µg/ml.

Following administration of doxycycline hyclate at an actual dose of 10 mg/kg body weight steady state plasma concentrations ranged from 0.75 to 0.93 µg/g between 12 and 96 hours after start of medication.

Because doxycycline is highly lipid soluble, it has a good tissue penetration.

Respiratory tract tissue: plasma ratios of 1.3 (healthy lungs), 1.9 (pneumonic lungs) and 2.3 (nasal mucosa) have been reported for doxycycline. Plasma protein binding is high (over 90%).

Doxycycline is scarcely metabolised. Doxycycline is primarily excreted with the faeces.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

Shelf life after first opening the immediate packaging: 1 year

Shelf life after dissolution according to directions: 24 hours

5.3 Special precautions for storage

Store below 30 °C.

Store in the original package.

Keep the bag tightly closed after first opening in order to protect from moisture.

Once opened, the veterinary medicinal product should be stored at temperatures below 25 °C.

5.4 Nature and composition of immediate packaging

Alu triplex (PET/Al/PE) bags.

Alu quadriplex (PET/Al/PET/PE) bags.

Pack sizes of 100 g, 1 kg and 5 kg.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA, d. d., Novo mesto

7. MARKETING AUTHORISATION NUMBER

VM 01656/3053

8. DATE OF FIRST AUTHORISATION

8th September 2016:

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

July 2023

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

Approved 21 July 2023

